Skip to main content

Table 4 Hematological, clinical and radiation toxicities per patient (NCI/CTC) (ITT population, n = 70)

From: A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer

 

Induction therapy (n =70), n (%)

Consolidation therapy (n = 49), n (%)

 

All grades

Grade 3-4

All grades

Grade 3-4

Hematological toxicities per patient

    

Anemia

36 (51.4)

-

39 (79.6)

2 (4.1)

Neutropenia

31 (44.3)

17 (24.3)

20 (40.8)

1 (2)

Leukopenia

27 (38.6)

6 (8.6)

30 (61.2)

1 (2)

Thrombocytopenia

15 (21.4)

-

11 (22.4)

-

Febrile neutropenia (Pizzo)

2 (2.85)

-

Clinical toxicities (NCI-CTC)

    

Fatigue

31 (44.3)

2 (2.9)

23 (46.9)

-

Nausea

29 (41.4)

1 (1.4)

15 (30.6)

1 (2)

Vomiting

18 (25.7)

2 (2.9)

10 (20.4)

1 (2)

Diarrhea

11 (15.7)

-

5 (10.2)

-

Constipation

9 (12.9)

-

2 (4.1)

-

Anorexia

6 (8.6)

-

3 (6.1)

1 (2)

Hypercreatininemia

1 (1.4)

-

-

-

Radiation toxicities

    

Esophagitis

-

-

13 (26.5)

-

Skin injury

-

-

12 (24.5)

-

Dysphagia

-

-

6 (12.2)

-

Pain

-

-

3 (6.1)

 

Pulmonary radiation injury

-

-

1 (2)

1 (2)

Radiation mucositis

-

-

1 (2)

-

Pneumonitis

-

-

1 (2)

-

  1. Acute renal failure observed in 1 patient (G3 at induction).
  2. Acute radiation pneumonitis at 30 days post-completion observed for 1 patient.